ES2184084T3 - Estabilizacion de interferones en disolucion acuosa para la fabricacion de pastillas de administracion sublingual. - Google Patents
Estabilizacion de interferones en disolucion acuosa para la fabricacion de pastillas de administracion sublingual.Info
- Publication number
- ES2184084T3 ES2184084T3 ES97919596T ES97919596T ES2184084T3 ES 2184084 T3 ES2184084 T3 ES 2184084T3 ES 97919596 T ES97919596 T ES 97919596T ES 97919596 T ES97919596 T ES 97919596T ES 2184084 T3 ES2184084 T3 ES 2184084T3
- Authority
- ES
- Spain
- Prior art keywords
- manufacture
- interferons
- stabilization
- pads
- sublingual administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LOS INTERFERONES NATURAL Y RECOMBINANTE SE ESTABILIZAN CON AGUA BIDESTILADA, LACTOSA, ALBUMINA, MONO - Y DIHIDROFOSFATOS SODICOS, (C 5 H 10 O 5 ) N , COMO LA GOMA ARABIGA, Y SUELTOS Y DILUIDOS EN SOLUCION DE ETANOL AL 20% HASTA EL CUARTO LUGAR DECIMAL, POR PROCEDIMIENTO HOMEOPATICO. LA SOLUCION FINAL SE PULVERIZA SOBRE UN EXCIPIENTE QUE COMPRENDE UN 20% DE GOMA ARABIGA, UN 30% DE LACTOSA Y UN 50% DE ALMIDON PARA FABRICAR TABLETAS DE 100 MG, CADA UNA DE LAS CUALES CONTIENE 200 U.I. DE ALFA - INTERFERON HUMANO. LAS TABLETAS SE ADMINISTRAN SUBLINGUALMENTE AL PACIENTE PARA TRATAMIENTO DE INFECCIONES VIRALES SENSIBLES AL INTERFERON.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB9600433 | 1996-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2184084T3 true ES2184084T3 (es) | 2003-04-01 |
Family
ID=11004429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97919596T Expired - Lifetime ES2184084T3 (es) | 1996-05-09 | 1997-05-09 | Estabilizacion de interferones en disolucion acuosa para la fabricacion de pastillas de administracion sublingual. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0920329B1 (es) |
AP (1) | AP1168A (es) |
AT (1) | ATE224725T1 (es) |
AU (1) | AU2401197A (es) |
DE (1) | DE69715883T2 (es) |
DK (1) | DK0920329T3 (es) |
ES (1) | ES2184084T3 (es) |
WO (1) | WO1997041885A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP1168A (en) * | 1996-05-09 | 2003-06-30 | Feronpatent Ltd | Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets. |
AU730020B2 (en) * | 1997-05-09 | 2001-02-22 | Feronpatent Limited | Stabilisation of interferons in aqueous solution for manufacture of sublingually administered tablets |
WO1999006429A1 (fr) * | 1997-08-01 | 1999-02-11 | Toray Industries, Inc. | Stabilisation de proteines utiles et compositions a base de proteines utiles |
FR2836379B1 (fr) * | 2002-02-28 | 2007-06-01 | Dit Bon Michel Betend | Formes galeniques solides de medicaments homeopathiques, dont les allergenes ou antigenes, en dilutions homeopathiques pour preparation extemporanee pour un seul individu pour administration sublinguale |
AU2005235800B2 (en) * | 2004-04-23 | 2011-08-04 | Expedeon Limited | Methods and kits for stabilising, protecting and solubilising proteins |
JP2008501639A (ja) * | 2004-04-23 | 2008-01-24 | ノベシン リミテッド | タンパク質を安定化、保護及び可溶化させるための方法及びキット |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH156609A (de) * | 1931-01-27 | 1932-08-15 | Chem Pharm Lab Bika V Poehlman | Verfahren zur Herstellung eines trockenen, homöopathischen Heilmittels. |
EP0123291A2 (en) * | 1983-04-20 | 1984-10-31 | Kyowa Hakko Kogyo Co., Ltd. | Method for stabilizing interferon |
DE3484374D1 (de) * | 1983-08-04 | 1991-05-08 | Green Cross Corp | Gamma-interferonzusammensetzung. |
ZA878295B (en) * | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
FR2619714B1 (fr) * | 1987-09-02 | 1991-07-12 | Medibrevex | Nouvelles formes galeniques de theophylline pour administration par voie per- et sublinguale |
CA2024046A1 (en) * | 1989-09-28 | 1991-03-29 | Alberto Ferro | Stabilized leukocyte-interferons |
US5298261A (en) * | 1992-04-20 | 1994-03-29 | Oregon Freeze Dry, Inc. | Rapidly distintegrating tablet |
AP1168A (en) * | 1996-05-09 | 2003-06-30 | Feronpatent Ltd | Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets. |
-
1997
- 1997-05-09 AP APAP/P/1999/001682A patent/AP1168A/en active
- 1997-05-09 WO PCT/IB1997/000531 patent/WO1997041885A1/en active IP Right Grant
- 1997-05-09 AT AT97919596T patent/ATE224725T1/de not_active IP Right Cessation
- 1997-05-09 DE DE69715883T patent/DE69715883T2/de not_active Expired - Fee Related
- 1997-05-09 ES ES97919596T patent/ES2184084T3/es not_active Expired - Lifetime
- 1997-05-09 DK DK97919596T patent/DK0920329T3/da active
- 1997-05-09 EP EP97919596A patent/EP0920329B1/en not_active Expired - Lifetime
- 1997-05-09 AU AU24011/97A patent/AU2401197A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0920329A1 (en) | 1999-06-09 |
DE69715883T2 (de) | 2003-07-31 |
WO1997041885A1 (en) | 1997-11-13 |
DE69715883D1 (de) | 2002-10-31 |
ATE224725T1 (de) | 2002-10-15 |
AU2401197A (en) | 1997-11-26 |
EP0920329B1 (en) | 2002-09-25 |
AP9901682A0 (en) | 1999-12-31 |
DK0920329T3 (da) | 2003-01-27 |
AP1168A (en) | 2003-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2069582T3 (es) | Nucleosidos terapeuticos. | |
MY107843A (en) | Anti-viral compounds. | |
NO875209D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive 5-substituerte pyrimidin-nukleosider. | |
AR012614A1 (es) | Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento | |
WO1997049373A3 (en) | Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin | |
YU7296A (sh) | Farmaceutska kompozicija koja sadrži kombinaciju jedne protivvirusne supstance i jednog protivzapaljenskog glukokortikoida | |
ES2179040T3 (es) | Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b. | |
EA199901031A1 (ru) | Производные бензимидазола | |
ES2139132T3 (es) | Composiciones farmaceuticas activas en la terapia de desordenes del sueño. | |
AR020803A1 (es) | Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento | |
NO870441L (no) | Farmasoeytiske preparatformer for stabilisering av alfa-interferon. | |
BR9913333A (pt) | Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos | |
ATE63747T1 (de) | Antivirale verbindungen. | |
ES2184084T3 (es) | Estabilizacion de interferones en disolucion acuosa para la fabricacion de pastillas de administracion sublingual. | |
NO970847L (no) | 2-£amino-6-(cyklopropylamino)-9H-purin-9-yl|-2-cyklopenten-1-metanol-succinat som anti-virusmiddel | |
MX9301922A (es) | Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv). | |
ES2052922T3 (es) | Nucleosidos terapeuticos. | |
IT8722031A0 (it) | Formulazioni farmaceutiche e forme di dosaggio per la somministrazione rettale di calcitonina. | |
TR199900523T2 (xx) | Vir�s k�kenli hastal�klar�n tedavisi i�in farmas�tik bile�imler. | |
AU3354997A (en) | Topical composition containing amino acid in combination with either interferon or thymidine derivatives for treating viral or inflammation diseases | |
ATE371737T1 (de) | Proteaseresistente flint-analoge | |
ATE253938T1 (de) | Pharmazeutische kombination von antiviralen wirkstoffen | |
MX9303985A (es) | Nucleosidos terapeuticos. | |
EE9900346A (et) | Viljatusevastane ja viljastumisvõimet tõstev ravim | |
MY137298A (en) | Therapeutic nucleosides |